Literature DB >> 17103176

Citalopram-induced Raynaud's phenomenon.

A M Peiró1, C Margarit, M Torra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17103176     DOI： 10.1007/s00296-006-0254-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  14 in total

1.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

2.  Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia.

Authors:  J Rey; E Cretel; R Jean; M-J Pastor; J-M Durand
Journal:  Rheumatology (Oxford)       Date:  2003-04       Impact factor: 7.580

3.  Treatment of Raynaud's phenomenon with escitalopram.

Authors:  Ansgar Buecking; Estelle Rougemont; Daniele Fabio Zullino
Journal:  Int J Neuropsychopharmacol       Date:  2004-11-30       Impact factor: 5.176

Review 4.  Pathogenesis of Raynaud's phenomenon.

Authors:  A L Herrick
Journal:  Rheumatology (Oxford)       Date:  2005-03-01       Impact factor: 7.580

5.  Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report.

Authors:  C Bell; N Coupland; P Creamer
Journal:  Angiology       Date:  1996-09       Impact factor: 3.619

6.  Fluoxetine-induced Raynaud's phenomenon.

Authors:  A Rudnick; I Modai; A Zelikovski
Journal:  Biol Psychiatry       Date:  1997-06-15       Impact factor: 13.382

7.  [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases].

Authors:  M A Richard; F Fiszenson; M Jreissati; M J Jean Pastor; J J Grob
Journal:  Ann Dermatol Venereol       Date:  2001 Jun-Jul       Impact factor: 0.777

8.  Case of fluoxetine-induced remission of Raynaud's phenomenon--a case report.

Authors:  M A Bolte; D Avery
Journal:  Angiology       Date:  1993-02       Impact factor: 3.619

Review 9.  Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

Authors:  B Kahaleh; M Matucci-Cerinic
Journal:  Arthritis Rheum       Date:  1995-01

10.  Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon.

Authors:  J F Sunahara; M L Gora-Harper; K S Nash
Journal:  Ann Pharmacother       Date:  1996-05       Impact factor: 3.154
View more
  4 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 2.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

Review 3.  Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.

Authors:  Iqra Nawaz; Yashfa Nawaz; Eisha Nawaz; Muhammad Romail Manan; Adil Mahmood
Journal:  Cureus       Date:  2022-01-28

4.  Risperidone Related Raynaud's Phenomenon: An Adolescent Case.

Authors:  Serkan Güneş; Özalp Ekinci; Halenur Teke; Veli Yıldırım
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.